| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price targ...
TD Cowen analyst Joseph Thome initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Pric...
JP Morgan analyst Jessica Fye maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target fr...
Stifel analyst Dae Gon Ha reinstates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and announces $89 price target.